You are here: Industry Insights > tumours

News List

Siranomics begins phase-I trial of siRNA drug candidate STP707 to treat tumours ExpressPharma
February 11, 2022
The phase-I clinical trial, a multi-centre, open-label, dose-escalation and dose-expansion study, will evaluate the safety, tolerability and anti-tumour activity of STP707.
Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC expresspharma
August 04, 2020
The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/II STARTRK-NG study.
Nivolumab reduces size of some lung cancer tumours, relapse rate after surgery europeanpharmaceuticalreview
April 17, 2018
A drug given to early-stage lung cancer patients before they undergo surgery showed major tumour responses in the removed tumour…
Sorafenib improves progression-free survival for patients with rare sarcomas europeanpharmaceuticalreview
April 03, 2018
A randomised clinical trial shows that the drug sorafenib tosylate extended progression-free survival compared with a placebo…
Researchers use novel methods to determine drug uptake for tumours europeanpharmaceuticalreview
March 15, 2018
Researchers at the Moffitt Cancer Center in Florida have combined single-cell imaging of cancer cells in mice with mathematical modelling to establish which drug characteristics determine its efficacy.
Cancer vaccine eliminates tumours europeanpharmaceuticalreview
February 02, 2018
Injecting minute amounts of two immune-stimulating agents directly into solid tumours in mice can eliminate all traces of cancer…
Daiichi Sankyo enters licencing agreement with Boston Pharmaceuticals for RET inhibitor for solid tu pharmaasia
September 01, 2017
Daiichi Sankyo grants Boston Pharmaceuticals worldwide rights for the research, development, manufacturing and commercialisation of DS-5010.
Uncovering the cause of immunotherapy resistance in tumours europeanpharmaceuticalreview
July 27, 2017
Scientists have uncovered a key factor in the development of immunotherapy resistance in the case of cutaneous melanoma. This could potentially lead to future improvements in cancer therapy.
A new sensitive technique for detecting ovarian tumours biospectrumasia
April 14, 2017
Ovarian cancer is mostly diagnosed at such late stages that patients' survival rates are poor.
New research reveals caspase-2 enzyme deficiency increases risk of developing tumours pharmaceutical-technology
January 25, 2017
Researchers from the University of South Australia at the Centre for Cancer Biology have revealed that people with a deficiency of enzyme caspase-2 are at a higher risk of developing tumours.